Kris Fincher
Psychiatric/Mental Health · Kent, WANPI 1932358223
Payments from drug & device makers
Across 44 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$214
- Alkermes, Inc.$200
- Neurocrine Biosciences, Inc.$117
- AbbVie$107
- Johnson & Johnson$106
- Otsuka America Pharmaceutical, Inc.$60
- plus $155 from 3 others
What the payments were for
- Food & beverage$90795%
- Education$525%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $214 |
| Alkermes, Inc. | 10 | $200 |
| Neurocrine Biosciences, Inc. | 4 | $117 |
| AbbVie | 5 | $107 |
| Johnson & Johnson | 3 | $106 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Sunovion Pharmaceuticals Inc. | 5 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $52 |
| Indivior Inc. | 2 | $49 |
How this compares
$959 in reported general payments places this provider in the 75th percentile of 931 psychiatric/mental health providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 18 | $9,223 |
| Clozapine | 100 | $8,220 |
| Quetiapine Fumarate | 235 | $6,307 |
| Divalproex Sodium | 83 | $4,130 |
| Paliperidone ErPaliperidone | 13 | $3,751 |
| Olanzapine OdtOlanzapine | 31 | $3,372 |
| Ziprasidone Hcl | 28 | $3,236 |
| Olanzapine | 112 | $3,211 |
| Valproic Acid | 32 | $3,121 |
| Trazodone Hcl | 107 | $1,948 |
| Risperidone | 80 | $1,755 |
| Benztropine Mesylate | 83 | $1,385 |
| Carbamazepine | 13 | $1,077 |
| Aripiprazole | 40 | $1,042 |
| Sertraline Hcl | 42 | $1,040 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Kent
- Jenna VoKent$18K
- Agnes MarambaKent$14K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
- Janine TorresAuburn$24K
- Jennifer WilsonYakima$23K
- Patricia MorganKirkland$21K
- Kojo SarfoEllensburg$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.